TEVA-CAPTOPRIL 100 MG
CAPTOPRIL : 100 MG · DIN 01942999 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-CAPTOPRIL?
TEVA-CAPTOPRIL 100 MG contains CAPTOPRIL : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 01942999, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 06-Jul-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-CAPTOPRIL used for?
Treatment of essential or renovascular hypertension (usually with thiazide diuretics) and treatment of congestive heart failure (as concomitant therapy with a diuretic).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 01942999 |
|---|---|
| Brand name | TEVA-CAPTOPRIL |
| Generic / active ingredient | CAPTOPRIL : 100 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 100 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09AA01 CAPTOPRIL |
| AHFS class | 08:12.06.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 06-Jul-2011 |
| Original market date | 1995-12-31 00:00:00 |
How is it administered?
Hypertension: Initial dose 25 mg bid or tid. Heart Failure: Initial dose 6.25 mg or 12.5 mg tid. Start under close medical supervision. Take 1 hour before meals.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in the provided text.
How is it supplied?
Not explicitly detailed in provided text (mentions 12.5, 25, 50, and 100 mg strengths).
Contraindications
Hypersensitivity to captopril; history of ACE inhibitor-related angioedema; concomitant use with aliskiren-containing drugs in patients with diabetes or moderate to severe renal impairment.
Warnings and precautions
Serious Warning: Fetal toxicity. Risk of angioedema (may be fatal), neutropenia/agranulocytosis, proteinuria, and excessive hypotension (especially in salt/volume depleted patients).
What can be used instead?
Other Canadian products sharing ATC code C09AA01 CAPTOPRIL. 9 of 77 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-CAPTO TAB 100MG | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 00893625 |
| APO-CAPTO TAB 12.5MG | 12.5 MG | TABLET | APOTEX INC | MARKETED | DIN 00893595 |
| APO-CAPTO TAB 50MG | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 00893617 |
| NOYADA | 25 MG / 5 ML | SOLUTION | ETHYPHARM INC | MARKETED | DIN 02543915 |
| NOYADA | 5 MG / 5 ML | SOLUTION | ETHYPHARM INC | MARKETED | DIN 02543907 |
| TEVA-CAPTOPRIL | 12.5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 01942964 |
| TEVA-CAPTOPRIL | 25 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 01942972 |
| TEVA-CAPTOPRIL | 50 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 01942980 |
| APO-CAPTO TAB 25MG | 25 MG | TABLET | APOTEX INC | DORMANT | DIN 00893609 |
| APO-CAPTO TAB 6.25MG | 6.25 MG | TABLET | APOTEX INC | DORMANT | DIN 01999559 |
Who else supplies CAPTOPRIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CAPTOPRIL appears in 134 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.